New Data Show Lilly's Trulicity(R) (dulaglutide) in Combination with an SGLT-2 Inhibitor Improves Blood Sugar Control in People with Type 2 Diabetes

INDIANAPOLIS, Feb. 26, 2018 -- (Healthcare Sales & Marketing Network) -- Trulicity® (dulaglutide) significantly improves A1C (average blood sugar concentration over two to three months) when added to ongoing treatment with a sodium-glucose co-transpor... Biopharmaceuticals, Endocrinology Eli Lilly, Trulicity, dulaglutide, diabetes
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news